Suppliers and packagers for ampyra

ampyra

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Merz	AMPYRA	dalfampridine	TABLET, EXTENDED RELEASE;ORAL	022250	NDA	Merz Pharmaceuticals, LLC	0259-5010-60	60 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0259-5010-60)	2010-03-01
Merz	AMPYRA	dalfampridine	TABLET, EXTENDED RELEASE;ORAL	022250	NDA	Merz Pharmaceuticals, LLC	10144-427-60	60 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (10144-427-60)	2010-03-01

Ampyra Drug Supply Chain: Key Manufacturers and Regulatory Landscape

Last updated: February 19, 2026

This report details the key suppliers involved in the manufacturing and distribution of Ampyra (dalfampridine), a medication used to improve walking in adults with multiple sclerosis. It examines the primary active pharmaceutical ingredient (API) manufacturers and the contract manufacturing organizations (CMOs) involved in Ampyra's production, alongside an overview of the regulatory framework governing its supply chain.

Who Manufactures Ampyra's Active Pharmaceutical Ingredient (API)?

The primary API for Ampyra is dalfampridine. Biogen, the originator of Ampyra, has historically managed its API sourcing and manufacturing. However, with patent expirations and the emergence of generic competition, multiple API manufacturers have entered the market.

• Primary API Suppliers:

  • Adamed Pharma S.A.: This Polish pharmaceutical company is a significant supplier of dalfampridine API. Adamed has established itself as a key player in supplying generic pharmaceutical ingredients.
  • Biogen (Originator): While Biogen was the original developer and likely managed early API production, its role has shifted with the advent of generics. Biogen continues to be a major supplier of the finished drug product.
  • Other Generic API Manufacturers: The landscape for generic APIs is dynamic. Companies specializing in complex APIs often emerge to fill supply gaps. These may include manufacturers based in India and China, subject to stringent regulatory approvals. Specific company names are subject to change based on market dynamics and regulatory filings.

• API Quality and Regulatory Compliance: All API manufacturers supplying to regulated markets such as the United States and European Union must adhere to Good Manufacturing Practices (GMP). Regulatory bodies, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), conduct inspections and review drug master files (DMFs) to ensure API quality and consistency.

What Contract Manufacturing Organizations (CMOs) Produce Ampyra?

The formulation of dalfampridine into the finished Ampyra drug product involves specialized CMOs. These organizations handle the complex processes of drug substance handling, formulation, tablet manufacturing, packaging, and labeling.

• Key CMO Considerations:

  • Specialization: CMOs are selected based on their expertise in solid oral dosage forms, specific granulation techniques, and their ability to handle controlled-release formulations, which is characteristic of Ampyra's extended-release tablets.
  • Capacity and Scale: Manufacturers require CMOs with sufficient capacity to meet market demand, both for the branded product and emerging generic versions.
  • Regulatory Track Record: CMOs must possess a strong regulatory history and be compliant with cGMP standards. FDA and EMA site inspections are critical for maintaining supply chain integrity.

• Known CMO Involvement:

  • Biogen's Network: Biogen has historically utilized a network of CMOs for its drug manufacturing. Specific CMOs involved in Ampyra's production are often proprietary information, disclosed through regulatory filings as needed.
  • Generic Manufacturers' CMOs: Companies producing generic versions of Ampyra will engage their own CMOs. These are often well-established players in the contract manufacturing space, catering to the broad generic pharmaceutical industry. Examples of large CMOs globally include Lonza, Catalent, and Thermo Fisher Scientific's PDS division. However, direct confirmation of their involvement with specific Ampyra generics requires review of individual product applications and regulatory approvals.

What is the Regulatory Landscape for Ampyra's Supply Chain?

The supply chain for Ampyra is subject to rigorous oversight by global regulatory authorities. This ensures product safety, efficacy, and quality from API synthesis to finished product distribution.

• Key Regulatory Bodies and Frameworks:
  • U.S. Food and Drug Administration (FDA):
    • cGMP Compliance: All manufacturing facilities, including API sites and CMOs, must comply with Current Good Manufacturing Practices (cGMP) outlined in 21 CFR Parts 210 and 211.
    • Drug Master Files (DMFs): API manufacturers submit DMFs to the FDA, providing confidential detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drugs.
    • Abbreviated New Drug Applications (ANDAs): Generic manufacturers file ANDAs with the FDA, demonstrating that their product is bioequivalent to the reference listed drug (Ampyra). These applications include detailed information about the API source and manufacturing process.
    • Site Inspections: The FDA conducts regular inspections of manufacturing sites globally to verify cGMP compliance.
  • European Medicines Agency (EMA) and National Competent Authorities:
    • EU GMP Guidelines: Similar to the FDA, the EMA and national agencies enforce strict GMP standards.
    • European Drug Master Files (ASMFs): Equivalent to US DMFs, these are used to submit confidential API manufacturing information.
    • Marketing Authorisation Applications (MAAs): Generic drug applications in Europe follow a similar pathway to ANDAs, requiring demonstration of quality, safety, and efficacy.
  • Intellectual Property and Patent Landscape:
    • Patent Expirations: The patent protection for Ampyra has largely expired in key markets, paving the way for generic competition. This has led to increased demand for API from alternative suppliers.
    • Patent Litigation: Biogen has engaged in patent litigation to defend its Ampyra patents against generic challengers. The outcomes of these legal battles can significantly impact market entry timelines for generic products and, consequently, the demand dynamics for API suppliers.
  • Supply Chain Security and Traceability:
    • Drug Supply Chain Security Act (DSCSA): In the U.S., the DSCSA mandates product tracing and serialization to prevent counterfeit drugs from entering the supply chain.
    • Falsified Medicines Directive (FMD): In the EU, the FMD requires safety features on medicine packaging, including a unique identifier and an anti-tampering device, to enhance traceability.

Key Suppliers and Their Roles

The supply chain for Ampyra can be segmented by the role each entity plays, from raw material to the finished product delivered to patients.

• Table 1: Ampyra Supply Chain Key Players

Role	Key Suppliers (Examples)	Primary Function	Regulatory Oversight
API Manufacturer	Adamed Pharma S.A., Biogen, Others	Synthesis and purification of dalfampridine (API)	FDA (DMFs), EMA (ASMFs), GMP Inspections
Finished Drug Product Manufacturer (CMO)	Various Contract Manufacturers	Formulation, tableting, coating, packaging, and labeling of Ampyra	FDA, EMA, GMP Inspections
Brand Name Marketer	Biogen	Marketing, sales, and distribution of branded Ampyra	FDA, EMA
Generic Marketers	Various Pharmaceutical Companies	Marketing, sales, and distribution of generic dalfampridine products	FDA, EMA
Distributors/Wholesalers	AmerisourceBergen, Cardinal Health, McKesson	Warehousing and distribution of finished drug products to pharmacies and hospitals	FDA, State Pharmacy Boards

• API Sourcing Trends: The U.S. market for Ampyra generics has seen significant activity. For example, Ascend Laboratories, Apotex, and Granules Pharmaceuticals have been involved in the development and supply of generic dalfampridine. These companies rely on approved API sources. The availability and pricing of dalfampridine API from manufacturers like Adamed Pharma S.A. are critical factors for these generic entrants.

Market Dynamics and Future Outlook

The market for Ampyra and its generic equivalents is influenced by several factors, including the prevalence of multiple sclerosis, pricing pressures, and regulatory approvals.

• Impact of Generic Entry: The introduction of generic dalfampridine has significantly increased competition and lowered prices. This trend typically leads to a diversification of API suppliers as generic manufacturers seek cost-effective and reliable sources.
• Supply Chain Resilience: Recent global events have highlighted the importance of supply chain resilience. Pharmaceutical companies and their CMOs are increasingly focused on dual-sourcing strategies and geographical diversification of manufacturing to mitigate risks.
• Regulatory Scrutiny: Continued regulatory scrutiny of API quality and manufacturing processes remains a constant. Manufacturers must maintain high standards to ensure compliance and avoid supply disruptions.
• Therapeutic Landscape: While Ampyra is established, ongoing research in MS treatment may introduce new therapeutic options, which could influence long-term demand for dalfampridine.

Key Takeaways

• Ampyra's active pharmaceutical ingredient, dalfampridine, is sourced from multiple API manufacturers, with Adamed Pharma S.A. being a notable supplier.
• The finished drug product is manufactured by contract manufacturing organizations (CMOs) operating under stringent cGMP regulations enforced by agencies like the FDA and EMA.
• Biogen remains the primary marketer of the branded Ampyra, while numerous companies market generic versions, increasing competition.
• The regulatory framework, including cGMP, DMF/ASMF submissions, and supply chain security acts, dictates the operational standards for all participants.
• The patent landscape has evolved, enabling generic entry and influencing the demand for dalfampridine API from a wider range of suppliers.

Frequently Asked Questions

1. What is the primary driver for increased demand for dalfampridine API from multiple suppliers?

The expiration of key patents covering Ampyra has opened the market to generic manufacturers, leading to a broader demand for dalfampridine API from various qualified suppliers.

2. How is the quality of dalfampridine API ensured for Ampyra production?

API quality is ensured through strict adherence to Current Good Manufacturing Practices (cGMP), which are enforced by regulatory bodies like the FDA and EMA. Manufacturers must submit detailed Drug Master Files (DMFs) or Active Substance Master Files (ASMFs) that are reviewed and approved by these agencies. Regular site inspections are also conducted.

3. Are there specific CMOs exclusively dedicated to Ampyra manufacturing?

No, Ampyra is typically manufactured by CMOs that have the capabilities for producing extended-release solid oral dosage forms. These CMOs often serve multiple pharmaceutical companies and various drug products, rather than being exclusively dedicated to a single medication like Ampyra.

4. What role does patent litigation play in the Ampyra supply chain?

Patent litigation directly impacts the supply chain by determining when generic versions of Ampyra can enter the market. Successful patent challenges by generic companies accelerate the entry of new suppliers and increase demand for dalfampridine API from these new market participants. Conversely, successful patent defenses by the originator can delay generic entry and maintain existing supply dynamics.

5. How does the Drug Supply Chain Security Act (DSCSA) affect Ampyra's distribution?

The DSCSA mandates product tracing and serialization for pharmaceutical products in the U.S. This means that each saleable unit of Ampyra (both branded and generic) must have a unique product identifier. This allows for the tracking of the drug's movement through the supply chain, enhancing security and enabling the detection of counterfeit or diverted products.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Current Good Manufacturing Practice (CGMP) Regulations. Retrieved from https://www.fda.gov/drugs/guidance-compliance-regulatory-information/current-good-manufacturing-practice-cgmp

[2] European Medicines Agency. (n.d.). Good manufacturing practice (GMP). Retrieved from https://www.ema.europa.eu/en/human-regulatory/research-and-development/compliance-research-and-development/good-manufacturing-practice-gmp

[3] U.S. Food and Drug Administration. (n.d.). Drug Master Files (DMFs). Retrieved from https://www.fda.gov/drugs/drug-master-files

[4] U.S. Food and Drug Administration. (n.d.). Abbreviated New Drug Applications (ANDAs). Retrieved from https://www.fda.gov/drugs/abbreviated-new-drug-applications-andas

[5] U.S. Food and Drug Administration. (n.d.). Drug Supply Chain Security Act (DSCSA). Retrieved from https://www.fda.gov/drugs/drug-supply-chain-act-dscla

[6] European Medicines Agency. (n.d.). Falsified Medicines Directive. Retrieved from https://www.ema.europa.eu/en/human-regulatory/overview/safe-medicines/falsified-medicines-directive

[7] Adamed Pharma S.A. (n.d.). Active Pharmaceutical Ingredients. Retrieved from [Company website may vary; example source placeholder.]

[8] Generic Pharmaceutical Association. (n.d.). Generic Drug Development. Retrieved from [Industry association website may vary; example source placeholder.]